Provided by Tiger Fintech (Singapore) Pte. Ltd.

GT Biopharma Inc.

2.50
+0.15006.38%
Volume:18.61K
Turnover:46.98K
Market Cap:6.34M
PE:-0.36
High:2.70
Open:2.34
Low:2.34
Close:2.35
Loading ...
Apr 14, 2025

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Apr 04, 2025

Major Issues Report

Form 8-K - Current report
Mar 12, 2025

Correspondence

Form CORRESP - Correspondence
Feb 26, 2025

Major Issues Report

Form 8-K - Current report
Feb 21, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 07, 2025

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Jan 27, 2025

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Jan 27, 2025

Major Issues Report

Form 8-K - Current report
Dec 23, 2024

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Nov 28, 2024

Major Issues Report

Form 8-K - Current report
Nov 21, 2024

Major Issues Report

Form 8-K - Current report
Nov 15, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Sep 16, 2024

Major Issues Report

Form 8-K - Current report
Aug 15, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jun 27, 2024

Correspondence

Form CORRESP - Correspondence
Jun 27, 2024

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Jun 27, 2024

Major Issues Report

Form 8-K - Current report
Jun 26, 2024

Major Issues Report

Form 8-K - Current report
Jun 20, 2024

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Jun 07, 2024

Major Issues Report

Form 8-K - Current report